Moreover, the comparable inhibition of EZH2 and ASCL1 by HOC treatments both in progression and recurrence models demonstrate effective oncogenic transcription repression maintenance and consistent suppression of neuroendocrine lineage-determining transcription factors, which contributed to delayed or weakened tumor relapse. Here, ASCL1 is linked to neoplasm.